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Abstract 
Background: Nontuberculous mycobacteria (NTM)-mediated infections are a growing cause of worldwide morbid-
ity, but lack of rapid diagnostics for specific NTM species can delay the initiation of appropriate treatment regimens. 
We thus examined whether mass spectrometry analysis of an abundantly secreted mycobacterial antigen could 
identify specific NTM species.
Methods: We analyzed predicted tryptic peptides of the major mycobacterial antigen Ag85B for their capacity to 
distinguish Mycobacterium tuberculosis and three NTM species responsible for the majority of pulmonary infections 
caused by slow-growing mycobacterial species. Next, we analyzed trypsin-digested culture supernatants of these 
four mycobacterial species by liquid chromatography–tandem mass spectrometry (LC–MS/MS) to detect candidate 
species-specific Ag85B peptides, the identity of which were validated by LC–MS/MS performed in parallel reaction 
monitoring mode.
Results: Theoretical tryptic digests of the Ag85B proteins of four common mycobacterial species produced peptides 
with distinct sequences, including two peptides that could each identify the species origin of each Ag85B protein. 
LC–MS/MS analysis of trypsinized culture supernatants of these four species detected one of these species-specific 
signature peptides in each sample. Subsequent LC–MS/MS analyses confirmed these results by targeting these 
species-specific Ag85B peptides.
Conclusions: LC–MS/MS analysis of Ag85B peptides from trypsin-digested mycobacterial culture supernatants 
can rapidly detect and identify common mycobacteria responsible for most pulmonary infections caused by slow-
growing mycobacteria, and has the potential to rapidly diagnose pulmonary infections caused by these mycobacteria 
through direct analysis of clinical specimens.
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Background
Mycobacterium tuberculosis (Mtb) infections remain a 
major worldwide health threat, but the prevalence of 
debilitating pulmonary disease caused by nontubercu-
lous mycobacteria (NTM), which are ubiquitous envi-
ronmental pathogens, has been on the rise for decades 
[1–3] and is an important cause of morbidity in North 
America [4]. Population-based data from North America, 
Europe and Australia, and large tertiary care facility-
based studies in East Asia reveal that the incidence of 
NTM-related pulmonary disease continues to increase 
[1], with estimates ranging from 15.5 to 26.7 cases per 
100,000 adults > 50 years of age [4]. In South African and 
Asian countries, NTM infections also comprise a signifi-
cant fraction of suspected TB and multidrug-resistant 
TB (MDR-TB) cases [1], with NTM being responsible for 
4.2–30% of suspected TB cases [5–7] and 18–27% of sus-
pected “chronic” MDR-TB cases [8–11].
Accurate identification of the mycobacteria responsible 
for a pulmonary infection at the species/complex level is 
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critical for the selection of the appropriate antimicrobial 
therapy. This remains challenging, however, since Mtb 
and NTM patients may present with similar symptoms 
and nonspecific radiographic findings [12].
Mtb-specific diagnostic assays, such as IFNγ release 
assays (IGRAs), can detect Mtb exposure, but cannot 
distinguish between latent and active disease, and have 
received negative policy recommendations for diagnosis 
of active Mtb [13, 14]. Systematic review has also found 
that most IGRA results remain positive at the end of 
treatment [15]. Additionally, IGRAs can cross-react with 
antigens of M. kansasii and other NTM species [16, 17], 
increasing the odds of a misdiagnosis. Molecular assays 
for Mtb diagnosis, such as the Xpert MTB/RIF assay 
endorsed by the World Health Organization, allow PCR-
based detection of Mtb DNA in clinical specimens for 
rapid, sensitive and specific diagnosis [13], but cannot 
distinguish between viable and non-viable Mtb bacilli.
Acid-fast bacilli (AFB) smears commonly used as a first, 
rapid assay for diagnosis of mycobacterial infection are 
relatively insensitive and cannot distinguish between Mtb 
and NTM. Culture remains the gold standard for labora-
tory diagnosis of mycobacterial infections but requires up 
to 6  weeks for completion as well as significant technical 
expertise and analysis time to produce accurate micro-
organism identifications. Routine use of liquid media for 
mycobacterial cultures allows early detection of mycobacte-
ria in clinical specimens, but identification of the mycobac-
terium species present in positive broth cultures requires 
the use of costly commercial probes or time-consuming 
molecular methods. Matrix-assisted laser desorption ioni-
zation-time of flight mass spectrometry (MALDI-TOF MS) 
allows rapid and accurate species-specific identification of 
mycobacterial colonies from solid media and is becoming 
increasingly popular; however, its performance with posi-
tive mycobacterial broth cultures is dramatically hindered 
by low microbial biomass, the presence of more than one 
microorganism and/or proteinaceous material.
In contrast to Mtb, there are no commercially available, 
FDA-approved molecular assays for diagnosis of NTM 
infections from clinical samples, and multiple assays 
would be required to cover the spectrum of clinically rel-
evant NTM. Some large commercial or academic cent-
ers have laboratory-developed methods for one (i.e. M. 
avium) or multiple NTM species; however, these assays 
differ among these centers and are not standardized, lim-
iting their broader use by the clinical microbiology com-
munity. There are thus no satisfactory methods available 
for rapid and accurate NTM diagnosis.
LC–MS/MS represents an attractive means of iden-
tifying mycobacterial species using clinical or culture 
samples, since it can discriminate peptides derived from 
highly homologous proteins, such as virulence factors 
actively secreted by both Mtb and NTM. Antigen 85B 
(Ag85B) is an attractive candidate for this approach, 
since it represents the major secreted protein in the Ag85 
complex, which plays a key role in mycobacterial physiol-
ogy [18, 19]. Ag85 proteins can also be detected in sera 
[20–22], sputa [23] and cerebrospinal fluid (CSF) [22] 
and have been proposed as markers for Mtb diagnosis 
[24]. However, antibodies to Mtb Ag85 proteins used in 
diagnostic assays can cross-react with Ag85 homologues 
expressed by other mycobacterial species [25]. We now 
present evidence that LC–MS/MS analysis of mycobacte-
rial Ag85B tryptic digests can identify prominent myco-
bacterial species involved in pulmonary infections.
Methods
Sequence homology analysis of Ag85B proteins 
from common mycobacterial species
Querying the UniProt protein sequence database using 
the criteria “Ag85B”, “mycobacterium”, and selecting only 
those sequences with reviewed status and annotations 
scores ≥ 3 identified 11 full-length mycobacterial Ag85B 
protein sequences. These included entries from three 
Mtb strains (ATCC 25177/H37Ra and 25618/H37Rv and 
CDC 1551/Oshkosh), two M. bovis strains (ATCC BAA-
935 and BCG/Pasteur 1173P2), and single entries from 
M. avium, M. kansasii, M. scrofulaceum, M. intracel-
lulare (ATCC 13950), M. leprae TN, and M. smegmatis 
(ATCC 700084/mc (2)155). No strain information was 
available for the M. avium, M. kansasii, and M. scrofu-
laceum Ag85B protein entries. Clustal Omega (http://
www.uniprot.org/align/) was used to individually align 
the Ag85B sequence of Mtb ATCC 25177/H37Ra against 
each of the other 10 Ag85B sequence entries to deter-
mine percent identity and the number of identical and 
similar amino acids at aligned sequence positions (Fig. 1).
In silico analysis of Ag85B tryptic peptides
FASTA files of the UniProt Mtb ATCC 25177/H37Ra, M. 
avium, M. intracellulare (ATCC 13950) and M. kansasii 
Ag85B peptide sequences entries were imported into the 
Skyline software package and analyzed for tryptic cleav-
age sites, using default criteria for cleavage site assign-
ment, with the exception of allowing predicted cleavage 
sites to occur before proline residues.
Mycobacterial growth conditions and culture supernatant 
collection
Mycobacterium tuberculosis H37Ra, M. avium (ATCC 
35717), M. intracellulare (ATCC 13950) and M. kansasii 
(ATCC 12478) were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA). A 10 µL loop 
was used to inoculate mycobacterial colonies into 10 ml 
of protein-free Sauton’s broth (Himedia, West Chester, 
Page 3 of 10Zhang et al. Clin Proteom  (2018) 15:1 
?――――――――――――――――
M. tuberculosis A5U3Q3 MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGR 60
M. tuberculosis P9WQP1 MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGR 60
M. tuberculosis P9WQP0 MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGR 60
M. bovis P0C2T2 MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGR 60
M. bovis BCG A1KJU9 MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGR 60
M. kansasii P21160 MTDVSGKIRAWGRRLLVGAAAAAALPGLVGLAGGAATAGAFSRPGLPVEYLQVPSAAMGR 60
M. intracellulare Q49575 MTDLSEKVRAWGRRLVVGAAAAATLPGLIGIAGGAATANAFSRPGLPVEYLQVPSAGMGR 60
M. avium Q06947 MTDLSEKVRAWGRRLLVGAAAAVTLPGLIGLAGGAATANAFSRPGLPVEYLQVPSAGMGR 60
M. scrofulaceum Q50397 MTDLSKKVRAWGRRLLVGTAAAVTLPGLIGLAGGAPTAGAFSRPGLPVEYLQVPSAGMGR 60
M. leprae P31951 MIDVSGKIRAWGRWLLVGAA--ATLPSLISLAGGAATASAFSRPGLPVEYLQVPSEAMGR 58
M. smegmatis A0QU51 MTFIDKIRGHWARRMTVAAVAALLLPGLVGVVGGSATAGAFSRPGLPVEYLMVPSPSMGR 60
*  :. *.* : :.:.    **.*:.:.**: **.************ *** .***
____________________
M. tuberculosis A5U3Q3 DIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYS 120
M. tuberculosis P9WQP1 DIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYS 120
M. tuberculosis P9WQP0 DIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYS 120
M. bovis P0C2T2 DIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYS 120
M. bovis BCG A1KJU9 DIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYS 120
M. kansasii P21160 SIKVQFQSGGDNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSVIMPVGGQSSFYS 120
M. intracellulare Q49575 DIKVQFQSGGNGSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSVIMPVGGQSSFYA 120
M. avium Q06947 DIKVQFQSGGNGSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSVIMPVGGQSSFYA 120
M. scrofulaceum Q50397 NIKVQFQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIIMPVGGQSSFYS 120
M. leprae P31951 SIKVQFQNGGNGSPAVYLLDGLRAQDDYNGWDINTSAFEWYYQSGLSVVMPVGGQSSFYS 118
M. smegmatis A0QU51 DIKVQFQSGGPGSHAVYLLDGLRAQDDFNGWDINTNAFEMFLDSGLSVVMPVGGQSSFYS 120
.******.** .* *************:******* *** : :****::**********:
―――――――_________________
M. tuberculosis A5U3Q3 DWYSPACGKAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHP 180
M. tuberculosis P9WQP1 DWYSPACGKAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHP 180
M. tuberculosis P9WQP0 DWYSPACGKAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHP 180
M. bovis P0C2T2 DWYSPACGKAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHP 180
M. bovis BCG A1KJU9 DWYSPACGKAGCQTYKWETLLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHP 180
M. kansasii P21160 DWYSPACGKAGCTTYKWETFLTSELPQWLSANRSVKPTGSAAVGISMAGSSALILSVYHP 180
M. intracellulare Q49575 DWYQPACGKAGCSTYKWETFLTSELPQYLASNKGVKSTGSAAVGISMSGSSAMILAVNHP 180
M. avium Q06947 DWYQPACGKAGCSTYKWETFLTSELPSYLASNKGVKRTGNAAVGISMSGSSAMILAVNHP 180
M. scrofulaceum Q50397 DWYSPACGKAGCTTYKWETFLTSELPQYLQSNKSVKPTGSAAVGISMAGSSALILAAYHP 180
M. leprae P31951 DWYSPACGKAGCTTYKWETFLTSELPKWLSANRSVKSTGSAVVGLSMAGSSALILAAYHP 178
M. smegmatis A0QU51 DWYQPACGNNGCVTYKWETFLTSELPEWLAANRDVAATGNAAIGLSMAGSAALILAAYHP 180
***.****: ** ******:******.:* :*: *  **.*.:*:**:**:*:**:. **
_________________――――――――
M. tuberculosis A5U3Q3 QQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDP--AWERNDPTQQIP 238
M. tuberculosis P9WQP1 QQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDP--AWERNDPTQQIP 238
M. tuberculosis P9WQP0 QQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDP--AWERNDPTQQIP 238
M. bovis P0C2T2 QQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDP--AWERNDPTQQIP 238
M. bovis BCG A1KJU9 QQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKAADMWGPSSDP--AWERNDPTQQIP 238
M. kansasii P21160 QQFIYAGSLSALMDPSQGMGPSLIGLAMGDAGGYKASDMWGPSSDP--AWQRNDPSLHIP 238
M. intracellulare Q49575 NQFVYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKADAMWGPSSDP--AWQRNDPSLQIP 238
M. avium Q06947 DQFIYAGSLSALLDPSQGMGPSLIGLAMGDAGGYKADAMWGPSSDP--AWQRNDPSLHIP 238
M. scrofulaceum Q50397 QQFIYAGSLSALMDPSQGMGPSLIGLAMGDAGGYKASDMWGPSSDP--AWQRNDPTIQIP 238
M. leprae P31951 DQFIYAGSLSALMDSSQGIEPQLIGLAMGDAGGYKAADMWGPPNDP--AWQRNDPILQAG 236
M. smegmatis A0QU51 DRFIYAGSMSGFLNPSEGWWPFLINISMGDAGGYKANDMWGPTEDPNSAWKRNDPMVQIP 240
::*:****:*.::: *:*  * **.::*********  **** .**  **:****  :  
-------- ―――――
M. tuberculosis A5U3Q3 KLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPP 298
M. tuberculosis P9WQP1 KLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPP 298
M. tuberculosis P9WQP0 KLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPP 298
M. bovis P0C2T2 KLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPP 298
M. bovis BCG A1KJU9 KLVANNTRLWVYCGNGTPNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPP 298
M. kansasii P21160 ELVANNTRLWIYCGNGTPSELGGANVPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNLDA 298
M. intracellulare Q49575 ALVGNNTRLWVYCGNGTPSELGGANMPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFNA 298
M. avium Q06947 ELVGHNTRLWLYCGNGTPSELGGANMPAEFLENFVRSSNLKFQDAYNGAGGHNAVFNFNA 298
M. scrofulaceum Q50397 KLVGNNTRLWVYCGNGTPSELGGANMPAEFLENFVRSSNLKFQDAYNAAGGHNAVFHFDQ 298
M. leprae P31951 KLVANNTHLWVYCGNGTPSELGGTNVPAEFLENFVHGSNLKFQDAYNGAGGHNAVFNLNA 296
M. smegmatis A0QU51 RLVANNTRIWVYCGNGQPNELGGGDLPATFLEGLTIRTNETFRDNYIAAGGNNGVFNFPN 300
**.:**::*:***** *.**** ::** ***.:.  :* .*:* * .***:*.**::  
?_________
M. tuberculosis A5U3Q3 NGTHSWEYWGAQLNAMKGDLQSSLGAG----- 325
M. tuberculosis P9WQP1 NGTHSWEYWGAQLNAMKGDLQSSLGAG----- 325
M. tuberculosis P9WQP0 NGTHSWEYWGAQLNAMKGDLQSSLGAG----- 325
M. bovis P0C2T2 NGTHSWEYWGAQLNAMKGDLQSSLGAG----- 325
M. bovis BCG A1KJU9 NGTHSWEYWGAQLNAMKGDLQSSLGAG----- 325
M. kansasii P21160 NGTHSWEYWGAQLNAMKGDLQASLGAR----- 325
M. intracellulare Q49575 NGTHSWEYWGAQLNAMKPDLQSALGASSGGGG 330
M. avium Q06947 NGTHSWEYWGAQLNAMKPDLQGTLGASPGGGG 330
M. scrofulaceum Q50397 NGTHSWEYWGAQLNAMKPDLQGTLGATPGGGG 330
M. leprae P31951 DGTHSWEYWGAQLNAMKPDLQNTLMAVPRSG- 327
M. smegmatis A0QU51 NGTHNWAYWGRELQAMVPDLQRVLG------- 325
:***.* *** :*:**  *** *
Fig. 1 Sequence alignment of reviewed UniProtKB Ag85B protein sequences entries. Shaded amino acids indicate divergence from the consensus 
sequence of the Mycobacterium tuberculosis complex or the consensus sequence of all proteins with aligned sequence at that position. Sequences 
are segregated vertically into three groups: members of the mycobacterium tuberculosis complex (5), common pulmonary NTM (3), and other 
NTM causing human disease (3). Symbols indicate positions with complete conservation (*) or conservation between groups of amino acids with 
strongly (:) or weakly (.) similar properties. Lines above the sequence indicate observed and/or predicted tryptic peptides, with red font denot-
ing the NDPTIQQK peptide and its variant extension (dashed symbols) in other species, and amino terminal quesiton marks (?) denoting peptide 
sequences where one or more species contains an amino terminal proline reside expected to suppress cleavage
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PA). Cultures were grown at 37 °C in a shaker incubator 
(100 rpm) for 22 days, then centrifuged at 16,000×g for 
3 min, after which supernatants were removed, sterilized 
with a 0.22 μm filter (Millipore, Billerica MA) and stored 
at − 80 °C until use. Supernatant protein concentrations 
were determined with a BCA protein assay reagent kit 
(Pierce) using bovine serum albumin as the standard.
Tryptic digestion of mycobacterial culture supernatants
Mycobacterial culture media supernatant aliquots (100 
μL) were incubated for 40  min at room temperature 
with 5  mM Tris (2-carboxyethyl) phosphine  to reduce 
disulfide bonds, then incubated for 40  min at RT with 
55 mM iodoacetamide to alkylate cysteine residues, after 
which samples were protected from light. Samples were 
then digested using an optimized variant of a published 
microwave-assisted tryptic protein digestion protocol 
[26, 27]. Briefly, after addition of trypsin (Promega) to 
reaction mixtures at a 1:20 trypsin-to-protein mass ratio, 
samples floating in cold water were irradiated at 240 W 
for 5 min in a 1200 W microwave oven, with three rep-
etitions, after which samples were incubated at 37 °C for 
14  h. Samples were processed with SCX Ziptips (Mil-
lipore) to remove detergent and salt, concentrated by 
vacuum centrifugation, dissolved in 10 μL of 0.1% FA and 
then centrifuged at 16,000×g for 20 min, after which 7 μL 
samples were injected for LC–MS/MS analysis.
LC–MS/MS for peptide sequencing and analysis of MS data
Peptide analysis was performed on a nano-LC UltiMate 
3000 HLPC column coupled with a LTQ Velos Pro mass 
spectrometry system (Thermo Fisher Scientific, Waltham, 
MA, USA). Peptides were separated using EASY-Spray™ 
C18 LC Columns (15 cm × 75 μm I.D., 3 μm particle size) 
with a 0.3 μL/min flow rate and 120 min and 30 min lin-
ear gradients of 0.1% FA/5–30% acetonitrile for the data 
dependent acquisition (DDA) and parallel reaction moni-
toring (PRM) modes, respectively. For DDA, full MS scans 
were acquired over the m/z 200–2000 range, and the 
10 most intense peaks were fragmented with a collision 
energy of 30 and their product ions analyzed to determine 
the sequence of the precursor ion. Spectra were searched 
against the actinobacteria (class) protein database in Swis-
sProt using Mascot (version 2.3, Matrix Science, London, 
UK) using the following criteria: trypsin digestion with a 
maximum of 2 missed cleavage sites, precursor and product 
mass tolerances of 2 and 0.5 Da, cysteine carbamidometh-
ylation as a fixed modification and methionine oxidation 
as a dynamic modification. After peptide identification, 
[M + H]2+ precursor ions corresponding to Mtb NDPTQ-
QIPK (m/z 520.77), M. avium NDPSLHIPELVGHNTR 
(m/z 899.96), M. intracellulare NDPSLQIPALVGNNTR 
(m/z 854.95) and M. kansasii NDPSLHIPELVANNTR (m/z 
895.46) precursor and product ions (Additional file 1: Table 
S1) were applied as targets for MS analysis in PRM mode. 
Raw data were analyzed against the SwissProt actinobacte-
ria (class) protein database using Mascot software embed-
ded in Proteome Discoverer software (version 1.3, Thermo 
Scientific) to perform a match between the theoretical and 
experimental spectra, score these results and determine the 
false discovery rate using a target decoy control. Parameters 
used to generate the theoretical spectra were trypsin diges-
tion with no missed cleavage sites, precursor and product 
mass tolerances of 2 and 0.5 Da.
Results
Ag85B is highly conserved among mycobacterial species
A search of the UniProt protein sequence database using 
the search term Ag85B identified 11 reviewed entries cor-
responding to Ag85B sequence from three strains of Mtb, 
two strains of M. bovis, and six NTM species (M. avium, 
intracellulare, kansasii, smegmatis, scrofulaceum, and lep-
rae). Ag85B proteins from the three Mtb strains and M. 
bovis ATCC BAA-935—all of which cause tuberculosis—
demonstrated perfect sequence identity, while Ag85B from 
the non-virulent M. bovis BCG/Pasteur 1173P2 strain 
revealed a single amino acid mismatch. Ag85B sequences 
from the six NTM species also revealed significant full-
length homology to Mtb Ag85B, most demonstrating 
89.5–81.5% sequence identity, with only M. smegma-
tis Ag85B revealing less than 80% homology (Table  1), 
although conserved Ag85 sequence regions demonstrated 
uneven distribution in this alignment (Fig. 1).
Ag85B proteins of common mycobacterial pathogens 
exhibit distinctive tryptic peptides
Mass spectrometry can often differentiate highly 
homologous proteins by small differences in fragment 
Table 1 Sequence homology among reviewed Ag85B Uni-
Prot protein entries
Comparisons to M. tuberculosis ATCC 25177/H37Ra sequence with Clustal 
Omega
Mycobacterium species Entry Identity (%)
M. tuberculosis ATCC 25177/H37Ra A5U3Q3 100.00
M. tuberculosis ATCC 25618/H37Rv P9WQP1 100.00
M. tuberculosis CDC 1551/Oshkosh P9WQP0 100.00
M. bovis ATCC BAA-935 P0C2T2 100.00
M. bovis BCG/Pasteur 1173P2 A1KJU9 99.69
M. kansasii P21160 89.54
M. scrofulaceum Q50397 87.88
M. intracellulare ATCC 13950 Q49575 84.55
M. avium Q06947 83.33
M. leprae TN P31951 81.46
M. smegmatis ATCC 700084/mc(2)155 A0QU51 70.64
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ions observed in the MS/MS spectrum of their tryp-
tic peptides. To examine whether such peptide differ-
ences represent a potential means to distinguish among 
mycobacterial species responsible for clinical infections, 
we analyzed the Ag85B protein sequence of Mtb and 
the three slow-growing NTM most commonly associ-
ated with pulmonary NTM infections (M. avium, M. 
intracellulare, and M. kansasii) to identify species-
specific tryptic peptides (Table  2). Several of these 
peptides distinguished Mtb-derived Ag85B from homo-
logues expressed by one or more of these NTM, with 
two peptide regions identifying the Ag85B homologue 
secreted by each of these species. Specifically, Mtb Ag85B 
peptides PGLPVEYLQVPSAAMGR, VQFQSGGNG-
SPAVYLLDGLR, AGCQTYK, AADMWGPSSDPAWER, 
NDPTQQIPK and GDLQSSLGAG were all distinguish-
able from the corresponding peptides of each of the three 
NTM species. Only the predicted Mtb GDLQSSLGAG 
and NDPTQQIPK peptides and their corresponding 
NTM peptide variants could identify the Ag85B protein 
of each species. However, predicted M. avium and M. 
intracellulare variants of the Mtb GDLQSSLGAG pep-
tide required a cleavage event before a proline residue, 
which commonly occurs with greatly reduced frequency. 
M. avium and M. intracellulare had identical sequence 
for four predicted peptides (PGLPVEYLQVPSAGMGR, 
VQFQSGGNGSPAVYLLDGLR, AGCSTYK, and AAD-
MWGPSSDPAWER). Mtb and M. kansasii revealed iden-
tical WETFLTSELPQWLSANR peptides, while sequence 
variants of this peptide distinguished Ag85B derived 
from M. avium and M. intracellulare. Finally, all four spe-
cies had an identical SSNLK peptide.
LC–MS/MS analysis of Ag85B peptides differentiates 
common slow‑growing pulmonary mycobacterial 
pathogens
Based on these results, it appears that LC–MS/MS analy-
sis of Ag85B peptides from tryptic digests of mycobacte-
rial culture supernatants is likely to distinguish between 
Mtb and NTM infections and to identify specific NTM 
infections. To test this hypothesis we performed a proof-
of-concept study focusing on four species responsi-
ble for the majority of pulmonary infections caused by 
slow-growing mycobacteria: Mtb, M. avium, M. intracel-
lulare and M. kansasii. LC–MS/MS analysis of trypsin-
digested supernatants of positive mycobacterial broth 
cultures of these four mycobacteria detected a subset 
of their predicted Ag85B peptides (Table  3). LC–MS/
MS analyses of the Mtb culture sample detected four 
of its nine predicted Ag85B peptides, as well as a fifth 
peptide LWVYCGNGTPNELGGANIPAEFLENFVR 
excluded by the maximum length parameter of our in 
silico analysis. LC–MS/MS detected the Mtb NDPTQ-
QIPK peptide or a corresponding NTM peptide variant 
in positive liquid culture supernatants of all four species, 
but the Mtb VQFQSGGNNSPAVYLLDGLR and WET-
FLTSELPQWLSANR peptides and their matching NTM 
variants were detectable only in three of the four digests, 
with only the Mtb and M. kansasii samples revealing 
detectable levels of both peptides. Based on these results, 
the Mtb NDPTQQIPK peptide and its NTM sequence 
variants appear to have strong potential as discrimina-
tory biomarkers for these four mycobacterial species. 
LC–MS/MS did not detect NTM variants of the Mtb 
Table 2 Predicted Ag85B peptide ions detectable by LC–
MS/MS from mycobacteria commonly involved in pulmo-
nary disease
M. tb: M. tuberculosis; M. av: M. avium; M. in: M. intracellulare; M. ka: M. kansasii
[+ 57.0] indicates the m/z introduced by cysteine carbamidomethylation
Precursor ion (2+) Peptide sequence M. tb M. av M. in M. ka
892.972 PGLPVEYLQVP-
SAAMGR
+
885.964 PGLPVEYLQVPSAG-
MGR
+ +
913.977 PGLPVEYLQVP-
SPSMGR
+
1068.048 VQFQSGGNNSPAVY-
LLDGLR
+
1039.537 VQFQSGGNGSPAVY-
LLDGLR
+  +
1068.540 VQFQSGGDNSPAVY-
LLDGLR
 +
414.189 AGC[+ 57.0]QTYK +
393.676 AGC[+ 57.0]STYK + +
400.684 AGC[+ 57.0]TTYK +
1039.521 WETFLTSELPQWL-
SANR
+ +
993.496 WETFLTSELPSY-
LASNK
+
1014.010 WETFLTSELPQY-
LASNK
+
838.362 AADMWGPSSD-
PAWER
+
837.870 ADAMWGPSSD-
PAWQR
+ +
845.868 ASDMWGPSSD-
PAWQR
+
520.772 NDPTQQIPK +
394.225 LVANNTR +
899.963 NDPSLHIPELVGHNTR +
854.952 NDPSLQIPALVGNNTR +
895.463 NDPSLHIPELVANNTR +
274.656 SSNLK + + + +
452.722 GDLQSSLGAG +
642.315 PDLQGTLGASPGGGG +
637.305 PDLQSALGASSGGGG +
494.265 GDLQASLGAR +
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GDLQSSLGAG peptide, however, which were the only 
other peptides to exhibit species-specific discriminatory 
power in silico. The predicted M. avium and M. intracel-
lulare variants of this peptide require cleavage events at 
unfavorable sites before proline residues, but this ration-
ale does not apply to the M. kansasii peptide and the rea-
son for its absence is unclear.
To confirm the identity of the predicted Mtb Ag85B 
NDPTQQIPK peptide and its corresponding NTM 
peptide variants, we performed an LC–MS/MS analy-
sis using PRM mode to confirm the sequence of each 
of these peptides. The main transition ions for these 
peptides resolved at similar retention times in PRM or 
DDA mode LC–MS/MS analyses performed using the 
same preparation and chromatographic conditions. 
PRM product ions for the predicted Mtb NDPTQQIPK, 
M. avium NDPSLHIPELVGHNTR, M. intracellulare 
NDPSLQIPALVGNNTR and M. kansasii NDPSLHI-
PELVANNTR Ag85B peptides precisely matched their 
species-specific Ag85B sequence (Fig.  2). These results 
imply that tryptic peptides corresponding to this Ag85B 
region may represent a robust target for mycobacterial 
species identification.
Discussion
NTM cases have dramatically increased in the US and 
other developed countries over the past few decades, but 
this emerging healthcare challenge has not yet given rise 
to rapid and accurate diagnostic methods that can iden-
tify specific NTM. Clinical suspicion of NTM disease 
can increase after ruling out pulmonary Mtb infection, 
so that false-negative Mtb results can promote mistaken 
NTM diagnoses and the use of inappropriate mycobacte-
rial treatment regimens. Even accurately diagnosed NTM 
cases present clinical challenges, since several common 
NTM species exhibit different responses to available anti-
mycobacterial therapy regimens. A rapid assay that accu-
rately distinguishes between pulmonary TB and NTM 
cases, and identifies common NTM species responsible 
for pulmonary infections, would thus be of great value 
for rational treatment design. In the present work, we 
demonstrate that LC–MS/MS analysis of Ag85B peptides 
from early mycobacterial broth cultures provides rapid 
and accurate species identification.
Researchers attempting to develop Mtb-diagnostic 
immunoassays for use with clinical isolates have exam-
ined the utility of several Mtb-derived antigens, including 
Ag85 complex proteins, CFP-10/ESAT-6 [28], MPT64 
[29] and the phospholipid lipoarabinomannan (LAM) 
[30]; however, most of these factors are not appropri-
ate for NTM species identification. Mtb, M. kansasii, M. 
marinum and M. szulgai express CFP-10/ESAT-6, but 
other clinically important NTM, including mycobacte-
rium avium complex members, do not [31]. MPT64 is 
not a reliable marker for active TB cases since Mtb mpt64 
deletions and mutations can cause false-negative assay 
results [32], whereas LAM is a phospholipid and cannot 
reliably differentiate among mycobacterial species.
Ag85B plays a pivotal role in the synthesis of mycobac-
terial cell walls, and while it was first identified in Mtb, 
multiple NTM express homologues, including important 
pathogenic NTM species such as M. avium, M. intracel-
lulare and M. kansasii. Ag85B is also actively secreted 
and active Mtb cases can produce detectable levels of 
Ag85B in minimally invasive biological specimens, such 
as sputum and serum [20–23], suggesting its poten-
tial utility as a direct biomarker of mycobacterial bur-
den. Relatively few studies have examined its diagnostic 
potential using patient samples, but studies using serum 
and cerebrospinal fluid [21, 33] have observed moderate 
sensitivity (82 and 79%, respectively) with moderate to 
good specificity (86 and 97%). Ag85 complex proteins 
specifically interact with fibronectin [34] and exhibit 
robust sequence conservation across mycobacterium 
species, which may affect sensitivity and specificity of 
their detection by immunoassay methods. One recent 
study isolated mycobacteria from sputum samples using 
Table 3 Ag85B peptides detected in tryptic digests 
of mycobacterial culture supernatants
Organism [M + H]+ Charge Peptide sequence Intensity
Mtb 2135.1 2+ VQFQSGGNNSPAVY-
LLDGLR
6250
2078.0 2+ WETFLTSELPQWL-
SANR
2280
1040.5 2+ NDPTQQIPK 6420
3080.5 3+ LWVYCGNGTPNELG-
GANIPAEFLENFVR
460
904.4 2+ GDLQSSLGAG 3620
M. avium – – – –
1798.9 2+ WETFLTSELPSYLASNK 1186
1986.0 3+ NDPSLHIPELVGHNTR 30,428
– – – –
– – – –
M. intracellulare 2078.1 2+ VQFQSGGNGSPAVY-
LLDGLR
231
– – – –
1708.9 2+ NDPSLQIPALVGNNTR 1260
– – – –
– – – –
M. kansasii 2078.0 2+ VQFQSGGDNSPAVY-
LLDGLR
1523
1789.9 2+ WETFLTSELPQWL-
SANR
3261
2136.1 2+ NDPSLHIPELVANNTR 3510
– – – –
– – – –
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an Ag85B immunomagnetic enrichment approach 
prior to an Mtb-specific PCR analysis in an attempt to 
improve Mtb detection efficiency [35]. The sensitivity 
of this relatively labor-intensive approach for Mtb cases 
did not surpass Xpert-MTB/RIF assays results (89.9 vs. 
95.2%), and this study did not examine the diagnostic 
sensitivity of this method for common NTM species 
causing pulmonary disease. Regardless of its capacity to 
identify specific mycobacterium species, however, this 
approach cannot provide quantitative data, since it is 
unable to distinguish between DNA derived from viable 
and non-viable bacilli.
Culture remains the gold standard for laboratory diag-
nosis of mycobacterial infections, and while it is well doc-
umented that liquid media detects mycobacteria much 
earlier than solid media, rapid and accurate identification 
of mycobacteria from liquid broth cultures typically relies 
on costly commercial probes systems or time-consuming 
PCR and/or sequencing assays.
Our LC–MS/MS assay approach overcomes all these 
issues, directly detecting and identifying species-specific 
peptides derived from Ag85B secreted by positive myco-
bacterium broth cultures, to allow rapid and accurate 
identification of mycobacterium species. The diagnostic 
specificity of this approach does not suffer when used 
to analyze highly homologous proteins if the composi-
tion of the analyzed target peptides differs by at least one 
amino acid. While we have shown proof-of-principle 
results using supernatants from mycobacterium positive 
broth cultures, this method may also allow direct anti-
gen detection in clinical samples, yielding results that 
could quantify bacillary burden during the response to 
anti-mycobacterial treatment. We have recently applied a 
similar approach to quantify serum levels of the actively 
Fig. 2 Sequence confirmation of target Ag85B peptides from mycobacterial culture supernatants by LC–MS/MS PRM mode
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secreted Mtb antigens CFP-10/ESAT-6 [36], suggesting 
that a variation on this method could potentially identify 
and quantitate species-specific Ag85B proteins in patient 
serum samples. The ability to diagnose and identify spe-
cific NTM infections from serum samples would rep-
resent a significant advance over current methods that 
require positive mycobacterial culture samples for analy-
sis, and are thus limited by culture latency.
Mtb, members of the mycobacterium avium  complex 
(predominantly M. avium and M. intracellulare) and 
M. kansasii are the most common slow-growing myco-
bacterial species found to cause pulmonary disease in 
most of the US [37]. In this proof-of-concept study, we 
identified two predicted Ag85B-derived tryptic peptides 
that distinguish these four species, and verified that one 
of these peptides accurately identified positive liquid 
cultures derived from each of these species. Due to the 
high degree of amino acid sequence conservation among 
mycobacterial Ag85B protein homologues, however, rare 
but clinically important NTM species may share target 
peptide sequence with these mycobacterial species. Pro-
spective studies are required to determine the earliest 
time point for reliable species identification (e.g., at the 
first sign of broth culture positivity or before detecting 
growth by the continuous monitoring system), and to 
evaluate whether detection of Ag85B in serum samples 
can be used for species-specific diagnosis of NTM dis-
ease in complex clinical populations.
This approach has the potential for rapid clinical adop-
tion since it employs methods and equipment already 
in use in clinical laboratories, specifically mycobacterial 
broth culture and mass spectrometry. While MALDI-
TOF MS has shown remarkable performance for the 
identification of mycobacteria growing on solid media 
(colonies), its performance on positive mycobacterial 
broth (i.e. MGIT) is far less impressive. This constitutes 
a major limitation for the mycobacteriology laboratory, 
considering that mycobacterial broth cultures systems 
are more sensitive and detect growth earlier than solid 
media.  Our approach mimics an ELISA method pro-
posed to detect Mtb Ag85B in early mycobacterial culture 
filtrates for rapid Mtb diagnosis [23], while the high sen-
sitivity and specificity of MS supports the idea that our 
Ag85B detection method can function as a fast diagnos-
tic for NTM lung disease. Such an MS analysis approach 
can identify multiple mycobacterial species, and is much 
less subject to misdiagnosis of related mycobacteria, due 
to its ability to differentiate its target peptide sequence.
In summary, LC–MS/MS recognition of species-spe-
cific fragments of Ag85B from mycobacterial culture 
supernatants is a rapid, reliable and precise method to 
identify specific mycobacterial species. Future stud-
ies should address the diagnostic performance of this 
approach in clinical cohorts reflecting the variety of 
mycobacterial disease found in patient populations with 
a significant burden of NTM disease.
Conclusions
Our results indicate that a subset of tryptic peptide vari-
ants produced by multiple mycobacterial species can 
directly identify mycobacteria present in positive liquid 
cultures. This study analyzed peptides derived from tryp-
tic digests of three-week cultures of Mtb and three NTM 
responsible for the majority of pulmonary disease aris-
ing from slow-growing mycobacteria. Further analyses 
are necessary to determine the ability of this approach to 
discriminate among the spectra of mycobacteria encoun-
tered in large patient populations, the minimum time 
point at which mycobacterial cultures offer diagnosti-
cally useful information, and whether detection efficiency 
suffers in diagnostically challenging patient populations. 
Moreover, we hope to establish an optimized MS-based 
Ag85B assay that directly analyzes clinical samples, 
and validate its performance in a large, blinded patient 
cohort, to allow rapid identification of species responsi-
ble for suspected mycobacterial infections and to guide 
appropriate therapy regimens.
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